Sichenzia Ross Friedman Ference LLP Represents BioPharmX Corporation in $930,000 Registered Direct Offering
Press Release – New York, NY – September 29, 2016 – Sichenzia Ross Friedman Ference LLP announced today that it has represented BioPharmX Corporation (NYSE. MKT “ BPMX) in a Registered Direct public offering of 1,550,000 registered shares of its common stock at a price of $.60 per share and 1,240,000 unregistered warrants to purchase common stock at an exercise price of $.75 per share for gross proceeds to BPMX of $930,000. Rodman & Renshaw a Unit of H.C. Wainwright & Co., LLC acted as the exclusive Placement Agent for the offering. The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia, Marcelle Balcombe and Counsel Jeff Cahlon.
- SEC Extends Filing Deadlines for Public Companies and Registered Investment Advisers Affected by COVID-19 - April 1, 2020
- Business Interruption Insurance - April 1, 2020
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $7.7 Million Overnight Bought Offering of Cel-Sci Common Stock - March 26, 2020